Inhibition of the NLRP3 inflammasome improves lifespan in animal murine model of Hutchinson–Gilford progeria

González‐Dominguez, A., Montañez, R., Castejón‐Vega, B. , Nuñez‐Vasco, J., Lendines‐Cordero, D., Wang, C., Mbalaviele, G., Navarro‐Pando, J. M., Alcocer‐Gómez, E. and Cordero, M. D. (2021) Inhibition of the NLRP3 inflammasome improves lifespan in animal murine model of Hutchinson–Gilford progeria. EMBO Molecular Medicine, 13(10), e14012. (doi: 10.15252/emmm.202114012) (PMID:34448355) (PMCID:PMC8495449)

[img] Text
250961.pdf - Published Version
Available under License Creative Commons Attribution.

966kB

Publisher's URL: https://doi.org/10.15252/emmm.202114012

Abstract

Inflammation is a hallmark of aging and accelerated aging syndromes such as Hutchinson–Gilford progeria syndrome (HGPS). In this study, we present evidence of increased expression of the components of the NLRP3 inflammasome pathway in HGPS skin fibroblasts, an outcome that was associated with morphological changes of the nuclei of the cells. Lymphoblasts from HGPS patients also showed increased basal levels of NLRP3 and caspase 1. Consistent with these results, the expression of caspase 1 and Nlrp3, but not of the other inflammasome receptors was higher in the heart and liver of Zmpste24−/− mice, which phenocopy the human disease. These data were further corroborated in LmnaG609G/G609G mice, another HGPS animal model. We also showed that pharmacological inhibition of the NLRP3 inflammasome by its selective inhibitor, MCC950, improved cellular phenotype, significantly extended the lifespan of progeroid animals, and reduced inflammasome-dependent inflammation. These findings suggest that inhibition of the NLRP3 inflammasome is a potential therapeutic approach for the treatment of HGPS.

Item Type:Articles
Additional Information:This study was supported by a grant from the Progeria Research Foundation PRF 2021- 80 grant, Andalusian regional government (Grupo de Investigacion Junta de Andalucia CTS113 and Consejería de Salud de la Junta de Andalucia: PI-0036-2014). Dr. Gabriel Mbalaviele was supported by NIH/NIAMS AR068972 and AR076758 grants.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Castejon Vega, Dr Beatriz
Authors: González‐Dominguez, A., Montañez, R., Castejón‐Vega, B., Nuñez‐Vasco, J., Lendines‐Cordero, D., Wang, C., Mbalaviele, G., Navarro‐Pando, J. M., Alcocer‐Gómez, E., and Cordero, M. D.
College/School:College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine
Journal Name:EMBO Molecular Medicine
Publisher:EMBO Press
ISSN:1757-4676
ISSN (Online):1757-4684
Published Online:27 August 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in EMBO Molecular Medicine 13(10): e14012
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record